cles with rebound weight-gain after diet-restriction in rabbits. An important triad of nuclear hormone receptors comprises the peroxisome proliferator-activated receptors ␣, ␦, and ␥ (PPAR␣, ␦, and ␥), all of which are involved in energy homeostasis. They have in common a transcription function (termed AF-1) at the N-terminal region; a DNAbinding domain, consisting of two zinc fingers; and a dimerization domain and a hydrophilic pocket, which bind to the ligand in the C-terminal region. In order to bind to DNA, PPARs must form dimers with RXR, another nuclear receptor that is itself activated by 9-cis-retinoic acid.
The most widely explored member of the PPAR triad is PPAR␥, which is expressed mainly in adipocytes. PPAR␥ promotes adipocyte differentiation from fibroblasts (embryonic fibroblasts and embryonic stem cells during development) and promotes lipid storage in mature adipocytes by up-regulating genes for fatty acidbinding protein and acyl CoA synthetase. Its ligand is the prostaglandin 15-deoxy-D 12,14 -prostaglandin J 2 and the synthetic ligand, the drug thiazolidenedione (TZD). This drug has been used to improve insulin sensitivity in human patients suffering from type 2 diabetes. 1 The molecular mechanism of this effect is still unknown.
The receptor PPAR␣ is confined mainly to liver. In liver it exerts its action in the opposite direction from PPAR␥: it up-regulates genes in liver for lipid combustion, enhancing ␤-oxidation of fatty acids by acyl CoA oxidase and omega oxidation by cytochrome P450. In the food-deprived state, its activation causes a shift from carbohydrate to fat oxidation. When fed a high-fat diet, PPAR␣-null mice accumulate fat in their livers. PPAR␣'s ligands, apart from synthetic compounds of the fibrate class, include polyunsaturated fatty acids and eicosanoids, which are precursors of prostaglandins. 2 The function of PPAR␦ was recently elucidated in the laboratory of Wang et al. 3 PPAR␦ occurs in many tissues, but is most abundant in muscle, in which fatty acids are the preferred energy source. PPAR␦-null mice suffer from placental defects such that only few survive to birth 4 ; those that do show a systemic disturbance in lipid metabolism, by contrast to PPAR␥-null mice, in which the loss of function is confined to adipocytes and PPAR␣-null mice that have loss of function in liver.
The authors 3 studied the effect of "gain-of-function" with PPAR␦ in vivo, in particular the expression of the PPAR␦ gene in adipose tissue. The 78 -amino acid activation domain (VP16) of the herpes simplex virus was fused to the N-terminal end of PPAR␦. To ensure that the resulting fusion protein had the expected activity, the authors showed this protein to possess ligand-independent transactivation of a synthetic PPAR response element. In order to obtain expression of the VP16-PPAR␦ selectively in adipose tissue, the VP16-PPAR␦-cDNA was placed downstream of the fatty acid-binding protein gene promoter (aP2). The purified transgene was then injected into fertilized ova of C57BL6J ϫ CBA F1 mice. Transgene-positive offspring were selected and shown to express the VP16-PPAR␦ gene in adipose tissue under control of the aP2 gene. The transgenic mice, which harbored the VP16-PPAR␦ gene in their adipocytes, displayed a reduction in body weight (35% in 12 months) compared with wild-type litter mates; some of the transgenic mice lacked any visible white fat altogether, suggesting increased fatty acid oxidation. There was no reduction in number of adipocytes, but rather a reduction in the size and triglyceride content of adipocytes. Serum triglyceride levels were much reduced, although cholesterol levels remained unchanged.
To further explore their hypothesis that PPAR␦ in adipose tissue enhances fatty acid oxidation, the authors 3 fed a 35% (by weight) fat diet to 8-week-old transgenic mice and wild-type litter mates for 32 days (Figure 1) . The transgenic mice gained only 5.27 Ϯ 0.61 g (mean Ϯ SD) compared with the wild-type mice, which gained 12.40 Ϯ 0.76 g. The low weight gain in the transgenic mice was mainly due to inguinal, reproductive, and peritoneal fat of the transgenic mice, which weighed only 1/3 of that of the wild-type mice. Serum triglycerides and free fatty acids in the transgenic mice fed the high-fat diet remained at a low level; this result was similar to controls fed a chow diet, whereas the high-fat diet approximately doubled these parameters in the wild-type mice. The authors 3 concluded that PPAR␦ expressed in adipose tissue promoted fat oxidation and prevented diet-induced obesity.
To determine whether the leptin gene was involved in this effect, the authors 3 used db/db mice. This strain of mice becomes obese as a result of a mutation in the leptin receptor gene. 5 The VP16-PPAR␦ gene was transferred into adipocytes of db/db mice. Sixteen-week-old db/db mice were grossly obese, weighing 54.46 Ϯ 1.2 g, whereas the db/db-VP16-PPAR␦ mice weighed 31.70 Ϯ 1.37 g, similar to wild-type littermates; this result demonstrated that the PPAR␦ activation in adipose tissue is independent of leptin signaling.
Acting as ligand for PPAR␦, an agonist named GW 501516 was developed by Oliver et al. 6 by means of structure-based drug design. Administering this drug to obese db/db mice for only 7 days prevented the huge fat accumulation both in brown fat and liver in the mutant mice. Even without gene transfer into the adipocytes, therefore, a synthetic agonist can activate the PPAR␦ receptor of adipocytes.
To study the molecular mechanism of the greatly increased fatty acid oxidation promoted by PPAR␦ in adipocytes, the authors 3 determined expression of genes coding for fatty acid oxidation enzymes by Northern blot analysis of the enzymes' mRNA. They found that mRNAs for acyl CoA synthetases, acyl CoA oxidase, acyl CoA dehydrogenase, and carnitine palmitoyltransferase all had doubled in the adipose tissue of the transgenic mice. Most interesting was the finding of the effect of PPAR␦ activation on brown fat: mRNA for the uncoupling enzymes UCP1 and UCP3 was increased threefold. Therefore, not only does PPAR␦ in adipose tissue increase expression of enzymes for fatty acid oxidation, but it also causes uncoupling of oxidation from ATP formation in brown fat, leading to heat production at the expense of ATP. The authors 3 therefore designated PPAR␦ a "thermogenic transcription factor."
The conclusions arrived at from the in vivo experiments discussed above were confirmed in vitro. The authors 3 used 3T3L1 pre-adipocytes and allowed them to differentiate into mature adipocytes filled with triglycerides. They then infected the cells with adenoviruses harboring either the PPAR␦ or the VP16-PPAR␦ genes (or the VP16 gene, for control), and measured triglyceride metabolism by assay of glycerol released into the media. They found that overexpression of PPAR␦ in the adipocytes by infection with the PPAR␦ containing virus doubled the release of glycerol compared to control cells with the VP16 gene. Infection with the VP16-PPAR␦ gene-containing virus tripled the release. When the adipocytes were incubated with the specific synthetic PPAR␦ ligand, GW501516, the release of glycerol was stimulated even further, all within 6 hours. Intracellular triglycerides declined simultaneously with the increase in glycerol in the media. No free fatty acids were detected in the media along with the glycerol, showing that they were all oxidized. To clinch their conclusion that PPAR␦ stimulated fatty acid oxidation, the authors 3 infected adipocytes with viruses harboring PPAR␦ or VP16-PPAR␦ genes or treated them with the synthetic ligand GW501516 and then incubated them with [ 3 H]palmitic acid. In all cases, the treatment resulted in doubled [ 3 H]H 2 O production compared with control. An added synthetic PPAR␥ ligand had no effect.
Next, the investigators 3 determined the action of PPAR␦ on muscle cells, for muscle is the tissue in which this receptor is most abundant. Skeletal muscle cells C2C12 were allowed to differentiate into myotubules. When treated with the PPAR␦ agonist, GW501516, these muscle cells showed stimulated fatty acid oxidation and a much greater stimulation when infected with the VP16-PPAR␦-containing virus. Upon treatment of the cultured muscle cells with agonist, the mRNA of the heat-producing uncoupling enzyme, UCP2, increased significantly. The authors 3 concluded that PPAR␦ enhances ␤-oxidation and energy uncoupling (i.e., heat production) in muscle as well as in fat.
In summary, the in vivo activation of PPAR␦ in adipose tissue leads to up-regulation of energy expenditure by fatty acid oxidation. It results in lowered serum triglyceride and free fatty acid levels and decreased lipid accumulation. In vivo activation of PPAR␦ in adipose tissue protects against obesity and fatty liver in mice fed a high-calorie diet by activating the genes for ␤-oxidation of fatty acids. At the same time, PPAR␦ activates the heat-producing uncoupling enzymes in brown adipose tissue (UCP1 and 3) and muscle (UCP2). By accompanying increased uncoupling (i.e., decline in ATP production) with increased fatty acid oxidation (i.e., leading to ATP production), the organism can maintain its normal ATP/ADP ratio. 
